Stilgrip

Quick links to important sections

Stilgrip

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stilgrip

What is Stilgrip?

Property Description
Active ingredients Paracetamol, Phenylephrine, Chlorpheniramine Maleate, Caffeine
Form Oral Solid Dosage Form (e.g., tablet)
Pharmacological class Multi-component Cold and Flu Preparation
Common use Symptomatic relief of common cold and flu manifestations
Origin Synthetic Fixed-Dose Combination (FDC)

What Type of Medicine is Stilgrip and What is its Composition?

Stilgrip is a proprietary medicine classified as a multi-component cold and flu preparation, typically presented as an oral solid dosage form, such as a tablet. Its defining characteristic is its formulation as a Fixed-Dose Combination (FDC), which means it delivers four distinct active pharmaceutical ingredients in a single unit. This structure contrasts with single-ingredient medications and is recognized for providing effective relief for multiple symptoms simultaneously. The FDC strategy is a standard pharmacological approach designed to simplify the treatment regimen for patients experiencing a cluster of symptoms.


The Four Active Ingredients: Analgesic, Decongestant, Antihistamine, and Stimulant

The foundation of Stilgrip lies in its combination of four International Non-proprietary Name (INN) compounds: Paracetamol, Phenylephrine Hydrochloride, Chlorpheniramine Maleate, and Caffeine. Paracetamol is a widely used analgesic and antipyretic, included for managing pain and fever. Phenylephrine Hydrochloride is incorporated as a nasal decongestant, a key feature for improving airflow. Chlorpheniramine Maleate acts as a first-generation H1-receptor antihistamine to manage allergy-like symptoms. Unlike some non-stimulant cold remedies, Stilgrip's inclusion of Caffeine, a mild Central Nervous System (CNS) stimulant, is a differentiating feature designed to enhance the analgesic effect and help mitigate the potential drowsiness associated with the antihistamine component.


What is the General Purpose of Stilgrip?

The general purpose of Stilgrip is to provide comprehensive symptomatic relief from the key manifestations of the common cold and influenza. The combined action of the four pharmacological classes ensures that the preparation targets fever and pain, nasal congestion, and allergic symptoms concurrently. The formulation offers a coordinated pharmacological action intended to reduce patient discomfort, positioning it as a medicine used for the overall management of cold and flu symptoms during a typical episode of an upper respiratory infection.

What side effects are possible with Stilgrip?

Possible Side Effects and Safety Information

The official regulatory safety profile of this multi-component preparation reflects the combined characteristics of its active ingredients, addressing potential effects across multiple organ systems.

Adverse reactions are classified by frequency, with some of the more commonly documented effects impacting the Nervous System. These include drowsiness (sedation), dizziness, and headache. Conversely, due to the stimulant and decongestant components, effects like insomnia, restlessness, nervousness, and elevated blood pressure (hypertension) may also be reported.

Classification Representative Documented Adverse Reactions
Common Drowsiness, headache, dizziness, nausea, insomnia, increased blood pressure.
Very Rare Severe skin reactions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis).
Not Known Blood dyscrasias (e.g., agranulocytosis), palpitations, tachycardia, anaphylaxis.

Critical safety information documented in regulatory labels includes the risk of Severe Liver Damage or Liver Failure associated with the Paracetamol component, particularly in cases of overdose. The label includes a mandatory restriction against co-administration with any other Paracetamol-containing product to prevent cumulative toxicity.

Population-specific safety statements indicate that older adults may be more susceptible to neurological effects, such as confusion and dizziness. Caution is also explicitly advised for individuals with pre-existing conditions, including severe hypertension, heart disease, thyroid disease, or glaucoma, as the medicine's components may affect these conditions. Excessive intake of dietary caffeine must be avoided while using this product.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving this fixed-dose combination is officially classified as potentially life-threatening due to the risk of severe hepatic injury primarily linked to the Paracetamol component. Immediate medical attention is mandated by regulatory authorities upon any suspicion of overdose, and users are instructed to contact a Poison Control Center right away. Prompt medical assessment is critical for both adults and children, as the most serious complication, acute liver failure, may be delayed while initial signs remain non-specific.

Initial documented overdose presentations include non-specific symptoms such as anorexia, nausea, vomiting, and malaise. Effects on the Central Nervous System (CNS) are also recorded, including the potential for drowsiness or paradoxical excitability, with convulsions possible in severe scenarios. Excitability is noted to occur particularly in the pediatric population.

The official management protocol centers on the immediate administration of the specific antidote, Acetylcysteine. The efficacy of this treatment is highly time-dependent, diminishing significantly after the first eight hours following ingestion. Regulatory guidance requires laboratory monitoring, including levels of AST, ALT, and INR, to assess the degree of hepatic damage. Non-Paracetamol components are managed with symptomatic and supportive treatment.

Therapeutic Uses of Stilgrip

The primary therapeutic role of Stilgrip is to provide simultaneous, supportive relief for symptom clusters associated with the common cold and flu-like illnesses. The formulation is applied across domains where additional symptomatic support is needed to address the overall discomfort caused by acute respiratory episodes. The medication is generally used for managing symptoms such as fever, nasal congestion, headache, and minor aches, aligning with the therapeutic description of similar fixed-dose combinations.


Easing Systemic Discomfort and Nasal Symptoms

This therapeutic domain covers symptoms related to systemic imbalance and upper respiratory tract irritation. Stilgrip is commonly used to moderate distressing manifestations like fever, headache, and generalized body aches, as well as addressing nasal congestion, runny nose, and frequent sneezing. It provides support that helps ease the overall symptom burden during difficult episodes.

The medication is commonly used when symptoms create noticeable interference with daily stability, and may assist with maintaining a sense of stability when symptoms are more noticeable, contributing to improved day-to-day comfort.

Quick Fact: Support for Multi-Symptom Episodes The FDC is relevant in clinical settings that involve acute or unstable symptom patterns, and may assist with symptomatic support for concurrent fever, pain, and congestion.

Eligibility and Restrictions for Use

Who Can and Cannot Use Stilgrip?

Eligibility for this fixed-dose combination medicine is strictly defined by regulatory authorities based on a patient's age and pre-existing medical conditions.

Absolute Contraindications

Stilgrip is absolutely prohibited for use in patients with known hypersensitivity to any of its four active ingredients or in individuals with severe conditions, including severe liver impairment, uncontrolled hypertension, phaeochromocytoma, or closed-angle glaucoma. It must also not be used concurrently with other Paracetamol-containing products or by patients taking Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants.

Age and Physiological Status

Use is typically contraindicated for children under 6 years or under 12 years of age, depending on the specific product label. The medicine is not recommended for use in pregnant or breastfeeding patients due to potential risks associated with the Phenylephrine and Caffeine components.

Conditional Use

Use requires special caution and medical consultation for individuals with conditions such as non-severe renal or hepatic dysfunction, diabetes mellitus, and certain non-severe cardiovascular problems.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Stilgrip is established by official regulatory documents detailing mandatory prohibitions and restrictions necessary for safe co-administration with other medicines and substances. This profile strictly governs combinations that present risks of enhanced toxicity or exaggerated pharmacological effects.

The most restrictive category is the Contraindicated Combination, which includes Monoamine Oxidase Inhibitors (MAOIs), other Paracetamol-containing products, and other sympathomimetic decongestants. A strict timing-based rule mandates that Stilgrip must not be used for at least 14 days after the withdrawal of any MAOI, due to the risk of severe hypertensive interactions.

The risk of developing a hepatotoxic effect is increased when the Paracetamol component is co-administered with microsomal liver enzyme-inducing drugs, such as Rifampicin or Carbamazepine. Pharmacodynamic interactions include the potential for increased sedative effects when combined with alcohol or other Central Nervous System (CNS) depressant agents. Prolonged regular use of the Paracetamol component may also enhance the anticoagulant effect of Warfarin.

Furthermore, interactions that modify exposure are documented: Metoclopramide is stated to increase the absorption speed of the Paracetamol component, while Cholestyramine reduces it. Patients with hepatic impairment should note that the interaction hazard with enzyme-inducing drugs and alcohol is officially documented as elevated. Due to the caffeine content, excessive intake of dietary caffeine should also be avoided.

Mechanism of Action

Modulating Central Pain and Thermoregulation

This domain involves Paracetamol's mechanism of action, which primarily targets cyclooxygenase (COX) enzymes within the Central Nervous System (CNS). By inhibiting PGE2 synthesis in the hypothalamus and higher centers, the mechanism leads to the physiological consequences of resetting the body's thermal set point and modulating the intensity of central nociceptive signaling.

Controlling Nasal Vascular Tone and Secretions

This mechanistic domain combines two distinct actions: the alpha1-adrenergic agonism of Phenylephrine and the Histamine H1 receptor antagonism of Chlorpheniramine. This dual approach engages autonomic and inflammatory pathways to cause localized vasoconstriction and inhibit histamine-driven increases in capillary permeability, influencing mucosal tissue fluid dynamics and reducing capillary filtration.

Coordinating CNS Arousal and Analgesia

This domain addresses the sophisticated interaction of Caffeine with Paracetamol and Chlorpheniramine. Caffeine acts as an adenosine receptor antagonist to functionally counteract the sedative effect inherent to Chlorpheniramine's H1 blockade while simultaneously serving as an analgesic adjuvant, potentiating the central analgesic mechanism.

Dosage and Administration Information

Official Administration Guidelines for Stilgrip

Stilgrip is approved for oral administration as a fixed-dose combination tablet, which must be swallowed whole, typically with water. The official use pattern is defined by strict regulatory dosing limits for short-term symptomatic relief, and the medication is not intended for long-term or chronic application.


Standard Dosage and Frequency

The standard unit dose for adults and adolescents (generally 12 years and older) is one tablet. Administration follows a periodic schedule, typically taken three to four times a day as needed. To ensure the total daily exposure remains within regulatory limits, consecutive doses must be separated by a minimum interval, often specified as 4 to 6 hours. The maximum number of tablets permitted within a 24-hour period is strictly regulated and must not be exceeded.


Use Duration and Procedural Constraints

The prescribed use of Stilgrip is strictly short-term, limited to managing acute symptoms. Regulatory documents define the maximum continuous duration without medical guidance, which can range up to 10 days. A critical procedural constraint is the absolute prohibition against taking this medication concurrently with any other product containing Paracetamol (acetaminophen), as this could lead to the intake of a potentially toxic dose of the analgesic component. Furthermore, patients are directed to limit the intake of excessive dietary caffeine while using this formulation.


Population-Specific Use

Official labeling contains specific use principles for certain populations. The medicine is not recommended for use in children younger than 12 years. Caution and potential dose adjustment are procedural requirements for administration to older adults and individuals diagnosed with hepatic or renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Stilgrip

Evidence for Use in Common Cold and Flu-Like Symptoms

The research base for multi-component preparations like Stilgrip, which includes Paracetamol, Phenylephrine, Chlorpheniramine, and Caffeine, focuses primarily on researching the temporary discomfort of the common cold. Studies conducted during periods of increased symptom activity have primarily used short-term, randomized, double-blind, placebo-controlled trials (RCTs). These studies were generally applied in research contexts involving fluctuating or unstable symptoms experienced by otherwise healthy adults.

Research examined outcomes related to physical discomfort by using patient-reported scales, such as the Total Symptom Score (TSS). This composite measure tracks the perceived intensity of several simultaneous cold symptoms, including headache, fever, and nasal congestion. Studies examined patterns observed, where combining the components was assessed for its application to the cluster of symptoms associated with acute episodes. However, research exploring short-term symptom changes in these fixed-dose combinations is primarily limited to the acute phase, and long-term outcomes are not well characterized.

Studies Examining the Multi-Symptom Combination Approach

The rationale for fixed-dose combinations (FDCs) in cold treatment was evaluated in systematic reviews and regulatory assessments, which explored the strategic approach of combining ingredients with different effects—an analgesic, an antihistamine, and a decongestant. Research describes that the combination of these three distinct pharmacological classes was studied to explore whether it addresses a broader range of symptoms than single-ingredient therapies.

Research explored whether combining different components with established effects in single pill formats was associated with measured changes in a broader range of simultaneous symptoms, contributing to the broader evidence landscape for multi-component cold relief. However, comparative evidence is lacking when assessing this specific four-ingredient FDC directly against all possible competing combinations. The evidence primarily supports the principle of FDC use as a multi-component formulation.

Limitations and Current Scientific Discussion

Of particular note is the scientific discussion surrounding oral phenylephrine, which is included as a decongestant in this FDC. Regulatory committees in the United States, following an extensive review of available data, have expressed a consensus that the current scientific data do not support that orally administered phenylephrine demonstrates effectiveness in its role as a nasal decongestant at the recommended dosage. This finding does not alter the regulatory status of the analgesic or antihistamine components but introduces uncertainty regarding the evidence base for its role in nasal decongestion. This regulatory finding applies only to oral forms.

Frequently Asked Questions (FAQ)

Common questions about Stilgrip (FAQ)


Q: Is Stilgrip available without a prescription?

The regulatory status of Stilgrip is determined by the specific country's classification of its active ingredients. Official regulatory information indicates the decongestant component is subject to specific classification, often resulting in Over-the-Counter (OTC) status with regulatory restrictions on purchase quantity.

Q: Can Stilgrip be taken at the same time as a multivitamin?

Official information emphasizes the importance of sharing a complete list of all concomitant products, including vitamins and mineral supplements, with a healthcare provider. This allows for a thorough check of potential interactions.

Q: What happens if a person forgets to take a dose of Stilgrip?

Official administration instructions detail the protocol for addressing a forgotten or missed dose. This information is designed to help maintain the appropriate time interval between doses.

Q: What is the shelf life of Stilgrip?

The medicine’s specific shelf life is the duration it remains chemically and physically stable for use. This period is stated on the authorized commercial packaging and detailed in the official regulatory stability section. Official guidance notes that the tablets should not be used past the expiry date printed on the label.

Q: Is Stilgrip safe to use if I have a history of kidney problems?

Official documents note that special caution is required for patients with pre-existing kidney (renal) impairment. Regulatory protocols indicate that administration in this population may necessitate a medical review and potential dose adjustment.

Q: Do older adults typically require a lower dose of Stilgrip?

Official regulatory labeling indicates that caution and potential dose adjustment are procedural requirements for administration to older adults. This is due to physiological changes that may affect how the medicine is processed and cleared from the body.

Q: Are there different strengths or forms of Stilgrip available?

Official drug labels list all approved dosage forms and strengths for Stilgrip. The available formats may include tablets, capsules, or even liquids, depending on the specific regulatory approval for the product.

Q: What should be done if someone accidentally takes too much Stilgrip?

Regulatory documents issue a strong caution that an overdose requires immediate medical evaluation. This is critical because of the risk of delayed but severe liver damage from the Paracetamol component, even if the person initially feels well.

Q: Is it true that Stilgrip is processed by the liver?

Official regulatory documents confirm that the active components of Stilgrip are extensively processed, or metabolized, primarily by the liver. This fact is the basis for the warnings regarding liver impairment and potential interactions with other enzyme-inducing drugs.

Q: Are allergic reactions to Stilgrip common?

The official safety profile lists severe allergic reactions, such as anaphylaxis, as being of 'Not Known' frequency. Other severe reactions, like severe skin rashes, are generally listed as 'Very Rare.' The frequency of allergic reactions should be confirmed in the specific official product information.

Q: Does Stilgrip have a known interaction with common pain relievers like ibuprofen?

Official regulatory documents list all major drug interactions, including mandatory prohibitions against other Paracetamol-containing products. This review includes combinations with common pain relievers to assess potential risks to the patient.

Q: What is known about the use of Stilgrip in patients with heart conditions?

Due to the Phenylephrine and Caffeine components, the medicine is strictly contraindicated in patients with severe, uncontrolled hypertension. Regulatory protocols specify that administration to individuals with other pre-existing cardiovascular problems requires special caution.

Q: Can Stilgrip cause problems with vision?

Official documents strictly contraindicate the medicine for use in patients with closed-angle glaucoma. Additionally, regulatory labeling often lists blurred vision or other visual disturbances as potential adverse effects associated with the antihistamine component.

Q: Is Stilgrip known to interact with blood pressure medications?

Official documents list Monoamine Oxidase Inhibitors (MAOIs) as a strictly forbidden combination due to the risk of severe hypertensive interaction. Caution is also noted for the co-administration of Stilgrip with other types of blood pressure medications.

Q: Are there any foods that should be avoided while using Stilgrip?

Official regulatory documents specifically restrict the intake of excessive dietary caffeine while using this medicine. Beyond caffeine, official guidance also mandates checking for other food or drink interactions that may influence the drug's processing.

Q: Can Stilgrip affect my ability to drive?

Due to the component Chlorpheniramine, which is known to cause drowsiness or dizziness, official regulatory documents carry a warning about impaired performance. Caution should be exercised regarding activities such as driving or operating heavy machinery until the medicine's effect is fully known.

Q: Has Stilgrip been studied in children?

Regulatory agencies conduct assessments to determine appropriate use in different age groups. Official product information defines the specific age limits and contraindications for use in children based on these studies and regulatory findings.

Q: How is Stilgrip eliminated from the body?

After the components are metabolized by the liver, official regulatory documents confirm that the inactive breakdown products are subsequently eliminated from the body. This process occurs primarily via renal excretion, commonly known as being cleared through the kidneys.

Q: Can Stilgrip affect laboratory test results?

Official regulatory labeling documents that the Paracetamol component of Stilgrip can potentially interfere with the results of certain laboratory tests. This interference may affect tests measuring blood glucose, uric acid, or other specific substances.

Q: Is Stilgrip known to cause dependence?

Stilgrip’s formulation, which contains four non-narcotic ingredients, is not typically classified as a controlled substance under federal drug schedules. This regulatory status indicates a low potential for abuse or dependence.

Q: Can Stilgrip be used while traveling internationally?

Regulations for traveling with medication are set by the destination country and can vary widely. Regulatory guidance recommends that medications be kept in their original containers, accompanied by appropriate documentation, and declared to customs where required.

Q: Is there a patient information leaflet available for Stilgrip?

Regulatory agencies in most regions require comprehensive patient information to be provided with the medicine. This includes a Patient Information Leaflet (PIL) or Medication Guide, which is made available to the public and patients receiving the medicine.

Q: How does the FDA classify the safety of Stilgrip?

Official labeling documents contain a detailed risk summary and recommendations for pregnant and breastfeeding patients, adhering to the FDA’s labeling rules. This safety assessment provides important context on potential risks based on available data.

Q: Why do some people need to avoid grapefruit while taking Stilgrip?

While official documents specifically restrict excessive dietary caffeine, they also mandate checking for other food/drink interactions. Products like grapefruit can interact with the metabolic enzymes in the body, which may influence the drug's processing.

Q: Is Stilgrip generally taken with or without food?

Official administration instructions, which are found in regulatory labeling, will specify the use condition related to food. This clarifies whether the medicine should be taken with food, without food, or if the food status does not affect its proper use.

Q: Does taking Stilgrip require special monitoring?

Depending on the patient’s pre-existing health conditions, regulatory guidance may require special monitoring. This can include follow-up appointments or laboratory tests to periodically check liver or kidney function.

Q: Does Stilgrip contain any common allergens like gluten or lactose?

Official regulatory documents, such as the full prescribing information, list all inactive ingredients and excipients. This detailed information is available to confirm the presence of common allergens like lactose or gluten in the final tablet formulation.

How should Stilgrip be stored and disposed of?

Official Storage and Disposal Instructions

Regulatory documentation specifies strict environmental conditions and handling procedures to maintain the integrity and safety of the Stilgrip medicine.

Requirement Type Official Instructions
Temperature Do not store the medicine above 25 C or 30 C, depending on the specific label, to preserve stability.
Environmental Protection Keep the product in its original container to protect it from light and moisture.
Child Safety The medicine must be kept out of the sight and reach of children at all times.
Stability Do not use the tablets after the expiry date printed on the packaging.
Disposal Unused or expired product must not be disposed of in household waste or wastewater. It must be returned to a pharmacist for proper disposal as pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Stilgrip found in:

A-Z Index: